Distant recurrence 10-41% well predicted by TN stage. How will these curves look with patients treated in current era? #bcsm https://t.co/Iz4rpgtn0L
RT @rschilsky: Continuous Risk! https://t.co/I6eyd0AQi0
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years https://t.co/eTZ0rZ7qSj https://t.co/JxrckelKhj
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years — NEJM https://t.co/OYHxDjX5fQ
RT @mzbaptista: 20 year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 years.The risk of distant rec was strongly…
RT @awolff: Humbling ... predictors of #ResidualRisk after standard adjuvant therapy are the new "holy grail". But once you have a test wi…
RT @IBCradiation: EBCTCG pulling together the big picture. Always rich papers. https://t.co/OBlLRpbCaG
This @NEJM study highlights the need to for new approaches to reduce the risk of late recurrence in #breastcancer https://t.co/buISfJ1JQy
RT @rschilsky: Continuous Risk! https://t.co/I6eyd0AQi0
RT @awolff: Humbling ... predictors of #ResidualRisk after standard adjuvant therapy are the new "holy grail". But once you have a test wi…
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
RT @awolff: Humbling ... predictors of #ResidualRisk after standard adjuvant therapy are the new "holy grail". But once you have a test wi…
EBCTCG metanalysis on risk of #BreastCancer recurrence after 5-year of #EndocrineTherapy just published @NEJM https://t.co/UQOCEbY636
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years — NEJM https://t.co/RrWAK5rGSL
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
RT @IBCradiation: EBCTCG pulling together the big picture. Always rich papers. https://t.co/OBlLRpbCaG
RT @Aiims1742: Risk of recurrence in hormone receptor + #breastcancer remains steady up to 20y @NEJM study by @hoosierdfh et al https://t.…
TNM staging not dead. Early, node negative disease still with lower risk. Will be interesting what will be out when we have 20 years of Oncotype/Mammoprint etc data https://t.co/q8urvCUDSt
RT @awolff: Humbling ... predictors of #ResidualRisk after standard adjuvant therapy are the new "holy grail". But once you have a test wi…
RT @DrHBurstein: Important @nejm data for late risk of breast cancer recurrence https://t.co/A79uyI6rVE
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
RT @Nikhilwagle: Meta analysis from EBCTCG: 20yr risk of recurrence of early stage ER+ breast cancer after 5yrs adjuvant endocrine therapy.…
Humbling ... predictors of #ResidualRisk after standard adjuvant therapy are the new "holy grail". But once you have a test with #ClinicalValidity, #ClinicalUtility implies knowing when to order it and knowing what to do with the result so as to impact cl
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
EBCTCG pulling together the big picture. Always rich papers. https://t.co/OBlLRpbCaG
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
RT @DrHBurstein: Important @nejm data for late risk of breast cancer recurrence https://t.co/A79uyI6rVE
RT @rschilsky: Continuous Risk! https://t.co/I6eyd0AQi0
RT @Aiims1742: Risk of recurrence in hormone receptor + #breastcancer remains steady up to 20y @NEJM study by @hoosierdfh et al https://t.…
RT @Nikhilwagle: Meta analysis from EBCTCG: 20yr risk of recurrence of early stage ER+ breast cancer after 5yrs adjuvant endocrine therapy.…
Risk for breast ca after only 5 yrs tx keeps going up! #bcsm https://t.co/xPDpqzynhr
RT @Nikhilwagle: Meta analysis from EBCTCG: 20yr risk of recurrence of early stage ER+ breast cancer after 5yrs adjuvant endocrine therapy.…
Risk of recurrence after 20 years remains significant and is associated with the TN status https://t.co/wepTjfN32s
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
RT @Nikhilwagle: Meta analysis from EBCTCG: 20yr risk of recurrence of early stage ER+ breast cancer after 5yrs adjuvant endocrine therapy.…
RT @DrHBurstein: Important @nejm data for late risk of breast cancer recurrence https://t.co/A79uyI6rVE
RT @DrHBurstein: Important @nejm data for late risk of breast cancer recurrence https://t.co/A79uyI6rVE
RT @DrHBurstein: Important @nejm data for late risk of breast cancer recurrence https://t.co/A79uyI6rVE
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
RT @Nikhilwagle: Meta analysis from EBCTCG: 20yr risk of recurrence of early stage ER+ breast cancer after 5yrs adjuvant endocrine therapy.…
Risk of recurrence in hormone receptor + #breastcancer remains steady up to 20y @NEJM study by @hoosierdfh et al https://t.co/dDhlLrNWRw Story by @maggiemfox Cites @JenniferLitton @MDAndersonNews Tough choices for patients! #bcsm https://t.co/ZHOnDQhDf
RT @Nikhilwagle: Meta analysis from EBCTCG: 20yr risk of recurrence of early stage ER+ breast cancer after 5yrs adjuvant endocrine therapy.…
RT @DrHBurstein: Important @nejm data for late risk of breast cancer recurrence https://t.co/A79uyI6rVE
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
RT @Nikhilwagle: Meta analysis from EBCTCG: 20yr risk of recurrence of early stage ER+ breast cancer after 5yrs adjuvant endocrine therapy.…
Meta analysis from EBCTCG: 20yr risk of recurrence of early stage ER+ breast cancer after 5yrs adjuvant endocrine therapy. @nejm @hoosierdfh https://t.co/Fa3G6lqliK
RT @DrHBurstein: Important @nejm data for late risk of breast cancer recurrence https://t.co/A79uyI6rVE
RT @DrHBurstein: Important @nejm data for late risk of breast cancer recurrence https://t.co/A79uyI6rVE
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
RT @DrHBurstein: Important @nejm data for late risk of breast cancer recurrence https://t.co/A79uyI6rVE
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
20y risk of #breastcancer after 5y HT is correlated to initial TN status and tumor grade -@NEJM https://t.co/974F6f4JEW
Riscos de 20 anos de recidiva do câncer de mama após parar a terapia endócrina aos 5 anos https://t.co/EbukRZiwow
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
Important @nejm data for late risk of breast cancer recurrence https://t.co/A79uyI6rVE
Continuous Risk! https://t.co/I6eyd0AQi0
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years — NEJM https://t.co/zcsqgJG1Nn
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
RT @NEJM: Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5…
Meta-analysis of 88 trials after 5 years of endocrine therapy shows #breastcancer recurrences steady to 20 years https://t.co/BQ5Oz3rCVQ https://t.co/VY5U7Wc6GI